Kazia 2018 Annual General Meeting Results

KEY TAKEAWAYS:

• Share with investors the results of the 2018 Annual General Meeting
• All resolutions were carried and total votes can be seen via the link below
• Almost 40% of the issued share capital was voted in this AGM, with approximately 90% of shares voted in favour of each resolution

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Annual General Meeting of shareholders.

All resolutions were carried. The vote totals can be found here.

Kazia Chairman, Iain Ross, commented “we are very pleased to have such an emphatic vote of confidence from our shareholders as the company moves forward. Almost 40% of the issued share capital was voted in this AGM, which is an extremely high turnout, and each of the resolutions were passed by a very decisive margin, with approximately 90% of shares voted in favour of each resolution. Kazia has an exciting year ahead, with four value-driving data read-outs from human trials expected, and we continue to be grateful for the support of our investors.”

About Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA)

Kazia Therapeutics is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

Register Interest